# Evan Castiglia

> Evan Castiglia is a seed investor at Thuja Capital backing Biotechnology and Health Care. See 3 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Thuja Capital](https://shizune.co/investors/profile/thuja-capital)
- Location: Amsterdam, The Netherlands
- Total investments: 3
- Last investment: Apr 2026
- Lead investor: 33%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/evancastiglia/?originalSubdomain=nl

Evan Castiglia is a Partner of Thuja Capital.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 2 | 67% |
| Health Care | 1 | 33% |
| Life Science | 1 | 33% |
| Therapeutics | 1 | 33% |
| Medical Device | 1 | 33% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 1 | 33% |
| Series A | 1 | 33% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| France | 1 | 33% |
| Germany | 1 | 33% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Tacalyx | Tacalyx develops therapeutics targeting cancer-specific carbohydrate antigens on the surface of metastatic malignant tumors where no satisfactory treatments exist.The name Tacalyx is derived from TACA (Tumor Associated Carbohydrate Antigen) and ‘lyx’ from the term Glycocalyx, the glycan-containing layer covering cells. Cancer cells differ fromnormal cells by displaying aberrant carbohydrate structures on their surfaces promoting metastasis, angiogenesis or suppression of the immune system. TACAs result from the aberrant glycosylation that is seen with transformation to a tumor cell and represent attractive targets for cancer treatment since they are displayed with high cancer specificity and enhance tumor virulence via the mentioned diverse mechanisms. | $12.9M | Seed | Apr 29, 2026 |  |
| Tacalyx | Tacalyx develops therapeutics targeting cancer-specific carbohydrate antigens on the surface of metastatic malignant tumors where no satisfactory treatments exist.The name Tacalyx is derived from TACA (Tumor Associated Carbohydrate Antigen) and ‘lyx’ from the term Glycocalyx, the glycan-containing layer covering cells. Cancer cells differ fromnormal cells by displaying aberrant carbohydrate structures on their surfaces promoting metastasis, angiogenesis or suppression of the immune system. TACAs result from the aberrant glycosylation that is seen with transformation to a tumor cell and represent attractive targets for cancer treatment since they are displayed with high cancer specificity and enhance tumor virulence via the mentioned diverse mechanisms. | $7.5M | Seed | Jun 11, 2024 |  |
| Gradient Denervation Technologies | Gradient Denervation Technologies develops a medical device for a transvascular treatment of pulmonary hypertension, based on prior research and intellectual property developed at Stanford University. | $15M | Series A | Sep 07, 2023 |  |

3 of 3 investments shown.

## Co-investors
- [Asabys Partners](https://shizune.co/investors/profile/asabys-partners) — VC Fund, 1 deal together
- [Boehringer Ingelheim Venture Fund](https://shizune.co/investors/profile/boehringer-ingelheim-venture-fund) — VC Fund, 1 deal together
- [Creathor Ventures](https://shizune.co/investors/profile/creathor-venture-management) — VC Fund, 1 deal together
- [Eurazeo](https://shizune.co/investors/profile/eurazeo-com) — VC Fund, 1 deal together
- [HTGF (High-Tech Gruenderfonds)](https://shizune.co/investors/profile/high-tech-gr%C3%BCnderfonds) — VC Fund, 1 deal together
- [Kurma Partners](https://shizune.co/investors/profile/kurma-life-science-partners) — VC Fund, 1 deal together

## About Thuja Capital

VC Fund · Utrecht, The Netherlands

Thuja Capital invests in early stage medical product innovations for diagnosis, cure, care or prevention.

4 contacts available at Thuja Capital.

| Name | Title | Profile |
| --- | --- | --- |
| Michel Briejer | Managing Partner | https://shizune.co/investors/profile/michel-briejer |
| Evan Castiglia | Partner | https://shizune.co/investors/profile/evan-castiglia |
| Florian Ludwig | Venture Partner | https://shizune.co/investors/profile/florian-ludwig-0542 |
| Harrold van Barlingen | Founder and Managing Partner | https://shizune.co/investors/profile/harrold-van-barlingen |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

## FAQ

### What does Evan Castiglia invest in?

Evan Castiglia invests primarily in Biotechnology, Health Care and Life Science startups, most often at Seed and Series A stage. Most of the 3 investments tracked by Shizune back companies in France. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Evan Castiglia last invest?

The most recent investment recorded for Evan Castiglia closed in Apr 2026. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co